Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shot up 9.1% on Thursday . The stock traded as high as $16.36 and last traded at $16.16, with a volume of 319,076 shares traded. The stock had previously closed at $14.81.

Several research firms recently weighed in on ADMS. Piper Jaffray Cos. restated an “overweight” rating and issued a $44.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. Cowen and Company restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. Mizuho upgraded Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 price target on the stock in a research note on Thursday, June 16th. Noble Financial began coverage on Adamas Pharmaceuticals in a research note on Friday, June 17th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, JMP Securities restated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $33.60.

The stock’s market cap is $335.43 million. The firm’s 50-day moving average is $16.06 and its 200-day moving average is $16.46.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.11. Equities analysts predict that Adamas Pharmaceuticals Inc. will post ($3.09) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its stake in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent SEC filing.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.